Lineage Cell Therapeutics announced Dec. 20 that it had entered into an exclusive worldwide collaboration and license agreement with Genentech, a member of the Roche group, for the development and commercialization of Lineage’s retinal pigment epithelium (RPE) cell therapy OpRegen. OpRegen, delivered subretinally in a single injection, targets advanced dry age-related macular degeneration (AMD) with geographic atrophy (GA)
Samsara Vision Files SEC Paperwork for $25 Million IPO to Advance IMT
Samsara Vision, of Far Hills, New Jersey, plans to raise $25 million in an initial public offering to advance a next-generation version of its Implantable Miniature Telescope (by Dr. Isaac Lipshitz), according to paperwork filed with the US SEC on Jan. 7. The company, previously known as VisionCare, plans to offer 4,166,667 shares of common stock at $6 per share …
Researchers Find that Prozac Blocks the Inflammation that Leads to Dry AMD
Researchers at the University of Virginia who were looking at the potential of repurposing non-ophthalmic approved drugs for the treatment of dry age-related macular degeneration (AMD) found that the antidepressant fluoxetine, commonly known as Prozac, blocks the inflammation that can lead to the blinding condition. An experimental drug called CY-09 has been found to block that inflammatory process by binding …
Sanofi to Invest up to $60 Million in Gyroscope Therapeutics
UK-based Gyroscope Therapeutics announced Nov. 8 that France’s Sanofi had committed to invest up to $60 million in equity in Gyroscope. Sanofi will invest $40 million initially, at a premium to Gyroscope’s prior Series C financing, and the remaining $20 million will be contingent on a future qualifying investment round and subject to certain closing conditions. Under the agreement, a …
EyeGate Pharmaceuticals Closes Acquisition of Bayon Therapeutics
EyeGate Pharmaceuticals announced that it has completed the planned acquisition of Bayon Therapeutics and has appointed Eric J. Daniels, MD, MBA, as its Chief Development Officer, effective as of October 21, 2021. Dr. Daniels will drive ongoing development of EyeGate’s pipeline of novel treatments for eye disease. This includes overseeing the development of a potential vision-restoring small molecule from Bayon, B-203, which …
US FDA Clears IND for 4DMT’s Wet AMD Gene Therapy Candidate
4D Molecular Therapeutics announced Oct. 6 that the US FDA had cleared the investigational new drug application (IND) for 4D-150 for wet age-related macular degeneration (wet AMD). 4D-150 is a dual-transgene intravitreal gene therapy that targets four distinct angiogenic factors, which 4DMT says has the potential for broad and durable efficacy after a single intravitreal administration in patients with wet …
FDA Approves Samsung Bioepis and Biogen’s Byooviz Lucentis Biosimilar (ranibizumab-nuna)
Samsung Bioepis and Biogen announced that the FDA has approved Byooviz (ranibizumab-nuna), a biosimilar referencing Lucentis (ranibizumab)i, for the treatment of wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV).
Visus Unveils Additional Ophthalmic Drug Candidates for Corneal Wound Healing, Glaucoma and AMD
During its inaugural Capital Markets Day in New York City, Visus Therapeutics unveiled additional ophthalmic drug candidates with applications in development for corneal wound healing, glaucoma and age-related macular degeneration (AMD). Additionally, the company introduced a novel drug delivery platform licensed from DelSiTech that has the potential to help optimize the clinical benefit of ophthalmic therapies.
AbbVie Makes Large Investment in Regenxbio’s Gene Therapy for Retinal Diseases
AbbVie and Regenxbio announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (AMD), diabetic retinopathy (DR), and other chronic retinal diseases. RGX-314 is currently being evaluated in patients with wet AMD in a pivotal trial utilizing subretinal delivery, and in patients with wet AMD and DR in two separate …
Apellis Announces Reports Mixed Phase 3 Results for Geographic Atrophy Drug; Will Pursue FDA Approval
Apellis Pharmaceuticals reported topline results from the phase 3 DERBY and OAKS studies evaluating intravitreal pegcetacoplan, an investigational targeted C3 therapy, in 1,258 adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Based on results from the studies, the company plans to submit a new drug application (NDA) for pegcetacoplan for GA to the FDA in the first half of 2022.
- Page 1 of 2
- 1
- 2
